ASC-J9® increases the bladder cancer chemotherapy efficacy via altering the androgen receptor (AR) and NF-κB survival signals

BACKGROUND: The current chemotherapy regimens may extend survival for patients with metastatic bladder cancer (BCa) for a few months, but eventually most patients succumb to disease because they develop resistance to their chemotherapy. METHODS: TCGA human clinical sample survey and urothelial tumor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Exp Clin Cancer Res
Main Authors: Huang, Chi-Ping, Chen, Jinbo, Chen, Chi-Cheng, Liu, Guodong, Zhang, Yong, Messing, Edward, Yeh, Shuyuan, Chang, Chawnshang
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6592003/
https://ncbi.nlm.nih.gov/pubmed/31234917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1258-0
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki